TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01648101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine 900mg/day
Description: Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine 600mg/day
Description: Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
Study: NCT01943305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis vaccine
Description: IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
Study: NCT03149354

Intervention type: OTHER
Group type: OTHER
Intervention: Assay of TSH, FT3 and FT4 by immuno-radiometric method
Description: Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
Study: NCT03551392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medx Console System
Description: This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Medx Console System
Description: This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vielight 810 intranasal stand alone unit
Description: Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Vielight 810 intranasal stand alone unit
Description: Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week.
Study: NCT01943305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccine
Description: STAMARIL, 1 dose (0.5 ml)
Study: NCT00307294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
Study: NCT01155232

Intervention type: DRUG
Intervention: Teriparatide
Description: Forteo (teriparatide)pen daily for 24 months

Intervention type: DRUG
Intervention: Teriparatide
Description: Forteo (teriparatide)pen daily for 24 months
Study: NCT03779139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrahepatic islets and islets in the omental pouch
Description: Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to 4000 IEq/kg delivered via intraportal route and the remainder implanted into a constructed omental pouch.
Study: NCT02839070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep/Wake Schedule
Description: Timing of sleep and wake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep/Wake Schedule
Description: Timing of sleep and wake
Study: NCT03779139

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrahepatic islets alone
Description: This is the standard of care procedure. Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to all islets autotransplanted intrahepatically via the intraportal route.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Volunteers
Description: These individuals will undergo metabolic testing as well as islet cell function testing.
Study: NCT04397263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
Study: NCT00275990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rheolytic thrombectomy with direct stenting
Study: NCT04122976

Intervention type: DRUG
Intervention: Darolutamide(Nubeqa, BAY1841788)
Description: The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
Study: NCT04186650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin
Description: Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
Study: NCT03924414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 100 ml (placebo) IV infusion
Study: NCT02115282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and archived tissue samples

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and archived tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02780583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kineret
Description: anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo injection administered every 6 hours along with intravenous methylprednisolone
Study: NCT01218958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 190 mg
Description: Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: IM injection once every 4 weeks for a total of 6 administrations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Medisorb naltrexone 190 mg
Description: IM injection once every 4 weeks for a total of 6 administrations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Medisorb naltrexone 380 mg
Description: IM injection once every 4 weeks for a total of 6 administrations.
Study: NCT02185430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion
Description: dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
Study: NCT02125851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xanthan Gum
Description: esophageal mucosal contact time vs sucralose slurry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey
Description: esophageal mucosal contact time of honey vs sucralose slurry
Study: NCT03070860

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan 18-FDG and 18-NAF
Description: Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG).
Study: NCT03126058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enhanced recovery after surgery
Description: Patients will undergo enhanced recovery after surgery programs.
Study: NCT00348699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFP464
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02453165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRANSVAGINAL SUTURE
Description: The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC SUTURE
Description: The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
Study: NCT03236259

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brainport high dose
Description: berry extract, high dose. Daily ingestion of capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brainport low dose
Description: Berry extract, low dose. Daily ingestion of capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin. Daily ingestion of capsule
Study: NCT01647243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative strength training
Description: Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
Study: NCT01829633

Intervention type: PROCEDURE
Intervention: Physiotherapy
Description: Shoulder physiotherapy with exercises
Study: NCT05534659

Intervention type: DEVICE
Intervention: Programmable valve
Description: Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.

Intervention type: DEVICE
Intervention: Non-programmable valve
Description: Non-programmable valve used in the study was Medtronic CSF-flow control valve.
Study: NCT00275990

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct stenting
Study: NCT02192931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Creatine monohydrate
Study: NCT04829903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Dulaglutide injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide injections
Study: NCT06094569

Intervention type: PROCEDURE
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices
Study: NCT00118963

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Tablets of 500 mg; 1000 mg two times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablets of 500 mg; 1000 mg two times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin BIAsp30 (Novolog 70/30)
Description: Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin BIAsp30 (Novolog 70/30)
Description: Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.

Intervention type: DRUG
Group type: OTHER
Intervention: Repaglinide
Description: Tablets of 1 mg; Dosage: 2 mg three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide
Description: Tablets of 1 mg; Dosage: 2 mg three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Metformin
Description: Tablets corresponding to 500 mg; two tablets two times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Repaglinide
Description: Tablet corresponding to 1 mg; two tablets three times daily.
Study: NCT02346630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules daily for 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa / Carbidopa
Description: Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armeo
Description: Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Armeo
Description: Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
Study: NCT00111345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracyclines
Description: 3x12 mg/qm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal daunorubicin
Description: 3x80 mg/qm
Study: NCT02234388

Intervention type: OTHER
Intervention: Observation
Description: There are no interventions associated with this registry as it is purely observational.
Study: NCT03210311

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression
Description: a compression stocking is worn, a garment compression class 2, flat knitted
Study: NCT02919683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Surgery
Study: NCT00111345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-CDA
Description: 2x6 mg/qm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AI
Description: AI
Study: NCT03275662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Fiber

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fermented Foods
Study: NCT04250636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS at 30mg/kg
Study: NCT04273594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemBloc
Description: Treatment with FemBloc for women who desire permanent birth control (female sterilization)
Study: NCT03447470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1
Study: NCT02112474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 1
Description: 9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 2
Description: 9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
Study: NCT01644006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
Study: NCT03537248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASP-57
Description: an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu® Multiplus
Description: a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
Study: NCT04053946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science Wounds Gels
Description: SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
Study: NCT02857543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-Based Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Heart Association Diet
Study: NCT03922347

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening program including 2 consecutive tests
Description: visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening program with mobile health
Description: Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
Study: NCT03359785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: TAK-831 Tablets.
Study: NCT04250636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS at 30mg/kg
Study: NCT03021512

Intervention type: PROCEDURE
Intervention: Phaco with Restor
Description: Phacoemulsification with bilateral bifocal intraocular lenses implantation
Study: NCT02857543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Study: NCT02231541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Very Low Frequency Magnetic Fields
Description: The device is set to an analgesic program lasting about 30 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Very Low Frequency Magnetic Fields
Description: The device is turned off.
Study: NCT03158376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo